Funder: Pfizer Inc.
Due Dates: April 8, 2026
Funding Amounts: 20,000–100,000 CAD per project; project duration up to 12 months; institutional overhead capped at 28%
Summary: Supports research and quality improvement projects to optimize HRRm testing and workflow integration for metastatic castration-sensitive prostate cancer in Canada, emphasizing sustainability and system-level impact.
Key Information: Projects must focus on implementation, workflow, or system improvement (not education-only or technical validation); only organizations in Canada are eligible.